

JOHNSON & JOHNSON  
Form 8-K  
March 21, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 21, 2019  
(Exact name of registrant as specified in its charter)

New Jersey I-3215 22-1024240  
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01 Other Events.

On March 21, 2019, Johnson & Johnson (the Company) determined that it will record an intangible asset impairment charge related to an in-process research and development asset, AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV), with a carrying value of approximately \$900 million acquired in the acquisition of Alios Biopharma Inc. in 2014.

Additional information became available which led the Company to the decision to abandon the development of AL-8176. The non-cash after tax impairment charge of approximately \$700 million represents the remaining intangible asset value related to AL-8176 and will be reflected in the Company's fiscal first quarter 2019 financial results and will be excluded for purposes of adjusted earnings.

The Company previously disclosed and recorded a non-cash after-tax partial impairment charge for AL-8176 in the fiscal third quarter of 2018 of approximately \$630 million. The charge was reflected in the Company's fiscal third quarter and full year 2018 financial results and was also excluded for purposes of adjusted earnings.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Johnson & Johnson  
(Registrant)

Date: March 21, 2019 By: /s/ Renee A. Brutus  
Renee A. Brutus  
Assistant Corporate Secretary